Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab.

Hümmert, Martin W

Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab. [electronic resource] - Multiple sclerosis and related disorders May 2018 - 87-89 p. digital

Publication Type: Case Reports; Journal Article

2211-0356

10.1016/j.msard.2018.03.021 doi


Adult
Alemtuzumab--therapeutic use
Antibodies, Monoclonal, Humanized--adverse effects
Brain Stem--diagnostic imaging
Daclizumab
Drug Substitution
Female
Humans
Immunoglobulin G--adverse effects
Immunologic Factors--adverse effects
Inflammation--etiology
Multiple Sclerosis--diagnostic imaging
Natalizumab--adverse effects